secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018735
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M
--------------------------------------------------------------------------------

- Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%.
- Full-year 2023 commercial revenue $49.8M (+46% YoY); net loss $35.4M ($1.40/share).
- Q1 2024 revenue guidance $14.8-15.6M; FY2024 guidance $78.5-84.5M (57-69% growth).
- Expects RECELL GO FDA launch May 31, 2024; sales team to expand to 108.
- Targeting cashflow breakeven and GAAP profitability no later than Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/0000950170-24-018735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024018735/rcel-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer